16.7 Menopausal Hormone Therapy

Menopausal Hormone Therapy (MHT): Indications & Prescribing Principles

Menopausal Hormone Therapy (MHT), formerly referred to as Hormone Replacement Therapy (HRT), is the most effective treatment for menopausal symptoms.

Evidence-Based Clinical Indications (FDA & The Menopause Society / NAMS)

1. Moderate-to-Severe Vasomotor Symptoms (VMS): Hot flashes and night sweats disrupting sleep or daytime functioning.
2. Prevention of Postmenopausal Osteoporosis: In individuals at high risk of osteoporotic fractures who cannot tolerate or have contraindications to non-hormonal antiresorptive agents.
3. Treatment of Genitourinary Syndrome of Menopause (GSM): Local low-dose vaginal therapies are preferred for isolated GSM.
4. Premature Hypoestrogenism: In individuals with Premature Ovarian Insufficiency (POI) or surgical bilateral oophorectomy prior to age 45.

The "Timing Hypothesis" (The Window of Opportunity)

Extensive secondary analyses of the Women's Health Initiative (WHI) and prospective trials (such as the ELITE and KEEPS trials) firmly established the Timing Hypothesis:

• Favorable Window: When MHT is initiated in individuals younger than 60 years of age OR within 10 years of menopause onset, the benefit-to-risk ratio is overwhelmingly favorable. In this early cohort, estrogen preserves vascular endothelial function, improves lipid profiles, reduces all-cause mortality, dramatically alleviates VMS, and reduces fracture risk without increasing coronary heart disease.
• Late Initiation (>60 Years or >10–20 Years Postmenopause): Initiating systemic MHT in older individuals with established, subclinical atherosclerotic plaques confers harm. Estrogen can induce plaque instability and inflammatory degradation, significantly increasing the risks of coronary events, ischemic stroke, and venous thromboembolism.

Core Architectural Principles of Menopausal Hormone Therapy
├── The Intact Uterus Decision Point (MANDATORY Uterine Protection Rule)
│   ├── Intact Uterus Present ──> MUST prescribe Estrogen PLUS Progestin (EPT)
│   │   └── Unopposed estrogen causes endometrial hyperplasia & adenocarcinoma!
│   └── Prior Hysterectomy (No Uterus) ──> Prescribe Estrogen ALONE (ET)
│       └── Progestin is unnecessary and slightly increases breast cancer risk
├── Systemic Estrogen Delivery Modalities
│   ├── Transdermal 17β-Estradiol (Patches, Gels, Sprays - Preferred First-Line)
│   │   └── Bypasses hepatic first-pass metabolism; NO increase in VTE or stroke risk
│   └── Oral Estrogen (Conjugated Equine Estrogens [CEE], Micronized Estradiol)
│       └── Undergoes hepatic first-pass; induces clotting factors & increases VTE risk
└── Progestin Selection for Uterine Protection
    ├── Micronized Progesterone (Prometrium 100–200 mg - Preferred)
    │   └── Metabolically neutral, breast-friendly, sedative (take at bedtime)
    ├── 52 mg Levonorgestrel IUD (LNG-IUD)
    │   └── Robust local endometrial suppression with minimal systemic absorption
    └── Synthetic Progestins (Medroxyprogesterone acetate [MPA])

[!CRITICAL] The Golden Rule of Menopausal Hormone Therapy:

• Estrogen ALONE (ET) is prescribed EXCLUSIVELY for individuals who have undergone a hysterectomy (no uterus).
• Estrogen PLUS a Progestogen (EPT) (or Estrogen + Bazedoxifene) is MANDATORY for all individuals with an INTACT UTERUS. Prescribing systemic estrogen alone to a woman with a uterus produces continuous, unopposed endometrial cellular proliferation, resulting in a 6- to 8-fold increase in endometrial hyperplasia and endometrial adenocarcinoma. Concurrent progestogen halts mitosis, induces secretory transformation, and neutralizes this neoplastic risk!

Systemic Estrogen Routes: Transdermal vs. Oral

• Transdermal 17β-Estradiol (Patches 0.025–0.1 mg/day, Gels, Sprays):
  • Mechanism: Absorbed directly across the dermis into the systemic venous circulation, completely bypassing hepatic first-pass metabolism.
  • Clinical Safety Profile: Does not stimulate hepatic synthesis of coagulation factors (Factor VII, VIII, prothrombin, fibrinogen) or Sex Hormone-Binding Globulin (SHBG). Large-scale observational studies and the ESTHER study confirm that transdermal estradiol confers NO statistically significant increase in the risk of Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or Ischemic Stroke.
  • Midwifery Indications: Preferred first-line formulation for all individuals, particularly those with obesity (BMI ≥30 kg/m²), tobacco use, mild controlled hypertension, hypertriglyceridemia, or gallbladder disease.
• Oral Estrogens (Conjugated Equine Estrogens [CEE] 0.3–0.625 mg, Micronized Estradiol 0.5–2.0 mg):
  • Mechanism: Absorbed via the portal circulation and metabolized heavily by the liver.
  • Clinical Profile: Induces hepatic prothrombotic proteins and elevates serum triglycerides, conferring a small but real increase in the absolute risk of VTE (2- to 4-fold relative increase) and ischemic stroke. May increase the incidence of cholelithiasis.

Progestogen Formulations for Endometrial Protection

• Micronized Progesterone (Prometrium, 100 mg daily continuous or 200 mg daily sequential for 12–14 days/month): Bioidentical to human ovarian progesterone. Highly preferred over synthetic progestins: lipid-neutral, does not elevate blood pressure, and observational cohorts (e.g., French E3N study) demonstrate a significantly more favorable breast safety profile compared to synthetic progestins. Patient counseling: Causes mild somnolence and relaxation due to neuroactive metabolites acting on GABA-A receptors; must be taken orally at bedtime.
• Synthetic Progestins (Medroxyprogesterone Acetate [MPA] 2.5 mg daily continuous or 5–10 mg cyclic): Effective endometrial protection, but can blunt estrogen's positive HDL-raising effects. The WHI trial linked oral CEE + MPA with a slight elevation in invasive breast cancer risk after 4 to 5 years of continuous use (an effect largely driven by the synthetic progestin).
• 52 mg Levonorgestrel IUD (LNG-IUD): Excellent off-label endometrial protection when paired with oral or transdermal systemic estrogen, providing profound local mucosal atrophy with negligible systemic progestin levels.

Local Vaginal Estrogen Therapy for Isolated GSM

For patients presenting solely with genitourinary symptoms (vaginal dryness, dyspareunia, recurrent UTIs) without bothersome vasomotor hot flashes, local vaginal estrogen therapy is the undisputed treatment of choice.

• Delivery Formulations: Low-dose estradiol vaginal tablets (10 mcg twice weekly), estradiol vaginal cream (0.5 to 1 g 2–3 times weekly), or an estradiol vaginal ring (Estring, replaced every 90 days).
• Physiologic Nuance: Extremely low therapeutic doses exert profound local trophic effects, restoring glycogen, lactobacilli, epithelial thickness, and acidic pH (<4.5), while serum estradiol concentrations remain entirely within the postmenopausal baseline reference range.
• Board Exam Golden Fact: Low-dose local vaginal estrogen does NOT require concurrent progestogen administration, even in women with an intact uterus, because it does not induce systemic endometrial proliferation!

Absolute Contraindications to Systemic MHT

Systemic Menopausal Hormone Therapy must never be prescribed in the presence of:

1. Active or past personal history of Breast Cancer.
2. Active or suspected Estrogen-Dependent or Progestin-Dependent Malignancy (e.g., endometrial adenocarcinoma).
3. Unexplained, undiagnosed Abnormal Genital / Uterine Bleeding (must rule out cancer with endometrial biopsy first!).
4. Active or past Venous Thromboembolism (DVT or Pulmonary Embolism).
5. Active or recent Arterial Thromboembolic Disease (Myocardial Infarction, Stroke, TIA).
6. Severe, active Liver Disease or Hepatic Impairment (inability to metabolize steroids).
7. Known high-risk thrombophilia (e.g., Factor V Leiden homozygous, Antiphospholipid Syndrome).
8. Porphyria cutanea tarda.

---